PDS Biotechnology Extends Cash Runway to Q3 2027, Advances PDS0101 to Phase 2
PDS Biotechnology extended its cash runway into the third quarter of 2027 after completing a financing round in Q1 2026. The company advanced its lead immuno-oncology candidate PDS0101 into Phase 2 head-and-neck cancer trials with pembrolizumab, targeting interim efficacy readouts by late 2026.
1. Cash Runway Extended
Management reported that proceeds from a Q1 2026 financing round will fund operations through at least the third quarter of 2027, reducing the risk of near-term capital needs.
2. Lead Candidate Progress
The company’s flagship immuno-oncology therapy, PDS0101, has entered Phase 2 combination trials with pembrolizumab in head-and-neck cancer, with enrollment underway and interim efficacy readouts targeted by late 2026.
3. Operational Focus
Executives emphasized disciplined cost management in Q1, reallocating resources toward late-stage development and out-licensing opportunities to optimize the pipeline’s value.